A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant
Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies – 90Y-ibritumomab tiuxetan is expensive and 131I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labell...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier Ltd.
2016
|
| Subjects: | |
| Online Access: | http://ir.unimas.my/id/eprint/12763/ http://ir.unimas.my/id/eprint/12763/1/A%20pioneerexperienceinMalaysiaonIn-houseRadio-labelling%28abstract%29.pdf |
| _version_ | 1848837270308651008 |
|---|---|
| author | Jew, Win Kuan Chiong, Soon Law Xiang, Qi Wong Ching, Tiong Ko Zool, Hilmi Awang Lee, Ping Chew Kian-Meng, Chang |
| author_facet | Jew, Win Kuan Chiong, Soon Law Xiang, Qi Wong Ching, Tiong Ko Zool, Hilmi Awang Lee, Ping Chew Kian-Meng, Chang |
| author_sort | Jew, Win Kuan |
| building | UNIMAS Institutional Repository |
| collection | Online Access |
| description | Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies – 90Y-ibritumomab tiuxetan is expensive and 131I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labelling 131I-rituximab might be the only viable practical option. We reported our pioneer experience in Malaysia on self-labelling 131I-rituximab, substituting autologous haematopoietic stem cell transplantation (HSCT) and a patient, the first reported case, received high dose 131I-rituximab (6000 MBq/163 mCi) combined with BEAM conditioning for autologous HSCT. |
| first_indexed | 2025-11-15T06:36:59Z |
| format | Article |
| id | unimas-12763 |
| institution | Universiti Malaysia Sarawak |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T06:36:59Z |
| publishDate | 2016 |
| publisher | Elsevier Ltd. |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | unimas-127632016-09-20T16:46:18Z http://ir.unimas.my/id/eprint/12763/ A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant Jew, Win Kuan Chiong, Soon Law Xiang, Qi Wong Ching, Tiong Ko Zool, Hilmi Awang Lee, Ping Chew Kian-Meng, Chang RM Therapeutics. Pharmacology Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies – 90Y-ibritumomab tiuxetan is expensive and 131I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labelling 131I-rituximab might be the only viable practical option. We reported our pioneer experience in Malaysia on self-labelling 131I-rituximab, substituting autologous haematopoietic stem cell transplantation (HSCT) and a patient, the first reported case, received high dose 131I-rituximab (6000 MBq/163 mCi) combined with BEAM conditioning for autologous HSCT. Elsevier Ltd. 2016 Article PeerReviewed text en http://ir.unimas.my/id/eprint/12763/1/A%20pioneerexperienceinMalaysiaonIn-houseRadio-labelling%28abstract%29.pdf Jew, Win Kuan and Chiong, Soon Law and Xiang, Qi Wong and Ching, Tiong Ko and Zool, Hilmi Awang and Lee, Ping Chew and Kian-Meng, Chang (2016) A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant. Applied Radiation and Isotopes, 116. pp. 13-21. ISSN 0969-8043 https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979287754&partnerID=40&md5=f2be2c3bb10247c1d16648a573219e73 http://dx.doi.org/10.1016/j.apradiso.2016.07.016 |
| spellingShingle | RM Therapeutics. Pharmacology Jew, Win Kuan Chiong, Soon Law Xiang, Qi Wong Ching, Tiong Ko Zool, Hilmi Awang Lee, Ping Chew Kian-Meng, Chang A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant |
| title | A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant |
| title_full | A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant |
| title_fullStr | A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant |
| title_full_unstemmed | A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant |
| title_short | A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant |
| title_sort | pioneer experience in malaysia on in-house radio-labelling of 131i-rituximab in the treatment of non-hodgkin's lymphoma and a case report of high dose 131i-rituximab-beam conditioning autologous transplant |
| topic | RM Therapeutics. Pharmacology |
| url | http://ir.unimas.my/id/eprint/12763/ http://ir.unimas.my/id/eprint/12763/ http://ir.unimas.my/id/eprint/12763/ http://ir.unimas.my/id/eprint/12763/1/A%20pioneerexperienceinMalaysiaonIn-houseRadio-labelling%28abstract%29.pdf |